(5,6,7,8- tetrahydronaphthalen- 1- yl)- (2- (1H- tetrazol- 5- yl)phenyl)amine

a putative potassium channel opener with bladder relaxant properties

Also Known As:

BL 1249; BL-1249; BL1249

Networked: 5 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Tetrahydronaphthalenes: 1
        (5,6,7,8-tetrahydronaphthalen-1-yl)-(2-(1H-tetrazol-5-yl)phenyl)amine: 5
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - (5,6,7,8-tetrahydronaphthalen-1-yl)-(2-(1H-tetrazol-5-yl)phenyl)amine: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - (5,6,7,8-tetrahydronaphthalen-1-yl)-(2-(1H-tetrazol-5-yl)phenyl)amine: 5

Experts

1.	García, Guadalupe: 2 articles (10/2021 - 01/2021)
2.	Murbartián, Janet: 2 articles (10/2021 - 01/2021)
3.	Martínez-Rojas, Vladimir A: 1 article (10/2021)
4.	Méndez-Reséndiz, Karina A: 1 article (01/2021)
5.	Oviedo, Norma: 1 article (01/2021)
6.	Belperio, John: 1 article (12/2020)
7.	Lopez, Benjamin: 1 article (12/2020)
8.	Nguyen, Victoria: 1 article (12/2020)
9.	Olcese, Riccardo: 1 article (12/2020)
10.	Schwingshackl, Andreas: 1 article (12/2020)

Related Diseases

1.	Lung Injury 12/15/2020 - "We treated HO-exposed mice and primary alveolar epithelial cells (AECs) with the novel TREK-1 activators ML335 and BL1249, and quantified physiological, histological, and biochemical lung injury markers. " 12/15/2020 - "Once-daily, intra-tracheal injections of HO-exposed mice with ML335 or BL1249 improved lung compliance, histological lung injury scores, broncho-alveolar lavage protein levels and cell counts, and IL-6 and IP-10 concentrations. " 01/01/2023 - "In mice, TREK-1 activation with BL1249 and ML335 counteracted IAV-induced histological lung injury and decrease in lung compliance and improved BAL fluid total protein levels, cell counts, and inflammatory IL-6, IP-10/CXCL-10, MIP-1α, and TNF-α levels. "
2.	Hyperalgesia 10/01/2021 - "Pre-treatment with BL-1249 prevented the pro-nociceptive effect of spadin on acute nociception and long-lasting mechanical allodynia and hyperalgesia in rats. " 01/01/2021 - "Intrathecal injection of BL-1249 (TREK-1 activator) reversed nerve injury-induced tactile allodynia, whereas spadin (TREK-1 blocker) produced tactile allodynia in naïve rats and reversed the antiallodynic effect induced by BL-1249 in neuropathic rats. " 10/01/2021 - "Besides, post-treatment with S300A, S333A or BL-1249 reversed long-lasting mechanical allodynia and hyperalgesia induced by formalin. " 10/01/2021 - "Local peripheral or intrathecal pre-treatment with BL-1249, selective opener of TREK-1, decreased long-lasting secondary mechanical allodynia and hyperalgesia induced by formalin. " 01/01/2021 - "In contrast, transfection of two low-activity TREK-1 recombinant channels with phosphomimetic mutations at those sites (S300D and S333D) produced tactile allodynia in naïve rats and interfered with antiallodynic effects of rottlerin/BL-1249 or Rp-cAMPs/BL-1249. "
3.	Neoplasms (Cancer) 10/01/2016 - "Notably, BL1249 inhibited both PDAC cell proliferation and migration indicating that hyperpolarization of Vm attenuates cancer cell behavior. "

Related Drugs and Biologics

1.	Interleukin-6 (Interleukin 6)
2.	Proteins (Proteins, Gene)
3.	potassium channel protein TREK-1
4.	Formaldehyde (Formol)
5.	rottlerin
6.	adenosine-3',5'-cyclic phosphorothioate

Related Therapies and Procedures

1.	Injections
2.	Spinal Injections